• Healthy Living
Will Facebook's organ donor success stick?
Can Facebook organ donor success stick?

On the first day of the initiative, there were 13,012 new …

Opinion: Alternative healing or quackery?
Alternative healing or quackery?

Dr. Paul Offit says some alternative therapists promote …

Product review: Battling the 'Over the Hill' myth
Skin: Battling the 'Over the Hill' myth

Do you remember that whole line of “Over the Hill” birthday …

Court: 'Pay to delay' generic drugs can be illegal
'Pay to delay' deals can be illegal

Reverse payment settlements arise when generic companies file a…

To ease shortage of organs, grow them in a lab?
Grow lab organs to ease shortage?

Two years ago, Angela Irizarry of Lewisburg, Pa., needed a …

Advertisement

Lilly drug chosen for Alzheimer's prevention study

Drug shows promise for milder forms of disease

Updated: Friday, 18 Jan 2013, 4:17 PM EST
Published : Friday, 18 Jan 2013, 4:17 PM EST

(AP) - Researchers have chosen an experimental drug by Eli Lilly & Co. for a large federally funded study testing whether it's possible to prevent Alzheimer's disease in older people at high risk of developing it.

The drug, called solanezumab, is designed to bind to and help clear the sticky deposits that clog patients' brains.

Earlier studies found it did not help people with moderate to severe Alzheimer's but it showed some promise against milder disease. Researchers think it might work better if given before symptoms start.

"The hope is we can catch people before they decline," which can come 10 years or more after plaques first show up in the brain, said Dr. Reisa Sperling, director of the Alzheimer's center at Brigham and Women's Hospital in Boston.

She will help lead the new study, which will involve 1,000 people ages 70 to 85 whose brain scans show plaque buildup but who do not yet have any symptoms of dementia. They will get monthly infusions of solanezumab or a dummy drug for three years. The main goal will be slowing the rate of cognitive decline. The study will be done at 50 sites in the U.S. and possibly more in Canada, Australia and Europe, Sperling said.

In October, researchers said combined results from two studies of solanezumab suggested it might modestly slow mental decline, especially in patients with mild disease. Taken separately, the studies missed their main goals of significantly slowing the mind-robbing disease or improving activities of daily living.

Those results were not considered good enough to win the drug approval. So in December, Lilly said it would start another large study of it this year to try to confirm the hopeful results seen patients with mild disease. That is separate from the federal study Sperling will head.

About 35 million people worldwide have dementia, and Alzheimer's is the most common type. In the U.S., about 5 million have Alzheimer's. Current medicines such as Aricept and Namenda just temporarily ease symptoms. There is no known cure.

Online:

Alzheimer's info: http://www.alzheimers.gov

Alzheimer's Association: http://www.alz.org

  • Comment Privately

Comment to 24 Hour News 8

Don't have a Facebook account? Or don't want to share something publicly? Email us here.

Report a comment

See a comment that should be moderated? Fill out the form here and tell us why.

Advertisement
  • Most popular stories right now
    No Stories Available
Advertisement

Advertisement